# Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment

> **NCT05132790** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Shengjing Hospital** · enrollment: 24 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** SHR-1316 at a dose 20mg/kg q3w
- **DRUG:** SHR6390 at a dose of 150mg orally, daily
- **RADIATION:** SBRT

## Key facts

- **NCT ID:** NCT05132790
- **Lead sponsor:** Shengjing Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-25
- **Primary completion:** 2024-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2024-01-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05132790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05132790, "Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05132790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*